Thermo Fisher Partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
Summary
Brno, Czech Republic, April 17, 2023 --( PR.com )-- ALPCO-GeneProof, a global leader in diagnostics, and Thermo Fisher announced a strategic partnership that brings the TaqPath Menu | GeneProof PCR kits to market. The partnership combines the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust supply chain and support systems.The portfolio to be delivered by Thermo Fisher is comprised of 37 CE-IVD molecular diagnostic assays from ALPCO-GeneProofs portfolio, built on its innovative “one workflow” technology, allowing for ease of use and compatibility with a wide range of qPCR instruments. Thermo Fisher plans to release the TaqPath Menu | GeneProof PCR kits in phases beginning with a panel for bloodborne and sexually transmitted infections (STIs). Founded in 2005, GeneProof offers a portfolio of more than 50 IVDD and 6 IVDR PCR test kits for infectious diseases and genetic mutations, as well as a suite of proprietary instrumentation for clinical laboratories of all sizes. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them.